Developer docs
API playgroundTry for free, no card

Search company profiles

Regenacy Pharmaceuticals

Full company profile

uuid0002pbk

Namestring
Regenacy Pharmaceuticals
Legal namestring
Regenacy Pharmaceuticals, Inc.
Websiteurl
regenacy.com
Company typeenum
Private
Founded yearint
2016
Short descriptiontext

Regenacy Pharmaceuticals is a clinical-stage biopharma developing ricolinostat, a first-in-class HDAC6 inhibitor, as a disease-modifying treatment for painful diabetic peripheral neuropathy, targeting diabetic neuropathy patients with plans to expand into China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
HDAC6 inhibitors, peripheral neuropathy treatment, diabetic neuropathy drugs, clinical-stage biopharmaceutical, nerve damage therapeutics
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Peripheral Neuropathy Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through the sale of prescription pharmaceutical products following regulatory approval. The company is developing ricolinostat as a treatment for peripheral neuropathies with plans to commercialize upon successful clinical trials and regulatory clearance.

businesswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company developing ricolinostat, a selective HDAC6 inhibitor drug candidate, as a potential first-in-class treatment for painful diabetic peripheral neuropathy (DPN). The product targets the underlying pathology of peripheral neuropathies rather than just symptomatic relief, and is being advanced through Phase 2 clinical trials with plans for international expansion including China markets.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Ricolinostat
CategoryPharmaceutical Drug Candidate
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeBroad incumbent
Description

Global biopharma with established neuropathic pain assets (e.g., pregabalin/Lyrica history) and broad diabetes pipeline; competes with Regenacy in the same neuropathy treatment space via both approved products and ongoing R&D.

TypeBroad incumbent
Description

Major biopharmaceutical company with a large diabetes franchise (dulaglutide/trulicity) and significant R&D presence in diabetic complications including DPN, making it both a potential competitor and a natural acquirer of neuropathy assets like ricolinostat.

TypeDirect peer
Description

Clinical-stage biopharma developing mechanism-driven therapies for diabetic complications and rare diseases; similar in size, stage, and focus on high-unmet-need diabetic indications, making it a directly comparable small-cap peer.

TypeBroad incumbent
Description

Japanese global biopharma with strong Asia-Pacific commercial infrastructure and a neuropathy/pain franchise; comparable both as a potential competitor and as a natural strategic partner for a US-Japan cross-border clinical asset.

5Viva Biotech
TypeEmerging player
Description

Asia-based discovery and development services/investor with biopharma incubation; comparable as both an investor in the same asset class and as an emerging player in the regional biopharma ecosystem in which Regenacy's syndicate operates.

TypeDirect peer
Description

Clinical-stage company developing a non-opioid therapy (NRD.E1) for painful diabetic peripheral neuropathy; a directly comparable small-cap peer targeting the same indication with a novel mechanism and similar development stage.

7Chromocell
TypeEmerging player
Description

Clinical-stage biotech developing novel therapeutics for pain and sensory disorders, including neuropathic pain; comparable in stage, scale, and therapeutic focus to Regenacy's single-asset DPN program.

TypeBroad incumbent
Description

Japanese global biopharma with active programs in diabetic complications and neurology; operates in the same therapeutic space and provides a natural regional commercialization partner for a US-developed neuropathy asset.

TypeEmerging player
Description

Clinical-stage company developing therapies for neuropathic pain and other neurological conditions; similar in size and stage, and competing for the same patient population and payer attention as Regenacy.

TypeDirect peer
Description

Clinical-stage biopharma developing mechanism-driven therapies, with a history of programs in diabetic complications and neuropathic pain; a directly comparable small-cap peer with overlapping therapeutic area focus.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regenacy Pharmaceuticals

Peripheral Neuropathy Therapeuticsregenacy.com

Regenacy Pharmaceuticals is a clinical-stage biopharma developing ricolinostat, a first-in-class HDAC6 inhibitor, as a disease-modifying treatment for painful diabetic peripheral neuropathy, targeting diabetic neuropathy patients with plans to expand into China.

Regenacy Pharmaceuticals firmographics

Firmographics
Name
Regenacy Pharmaceuticals
Legal name
Regenacy Pharmaceuticals, Inc.
Website
https://regenacy.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Regenacy Pharmaceuticals is a clinical-stage biopharma developing ricolinostat, a first-in-class HDAC6 inhibitor, as a disease-modifying treatment for painful diabetic peripheral neuropathy, targeting diabetic neuropathy patients with plans to expand into China.
Ownership category
akta.pro rank

Regenacy Pharmaceuticals industry classification

Industry
Product category
Peripheral Neuropathy Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • HDAC6 inhibitors
  • Peripheral neuropathy treatment
  • Diabetic neuropathy drugs
  • Clinical-stage biopharmaceutical
  • Nerve damage therapeutics

Where Regenacy Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Markets served

Regenacy Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through the sale of prescription pharmaceutical products following regulatory approval. The company is developing ricolinostat as a treatment for peripheral neuropathies with plans to commercialize upon successful clinical trials and regulatory clearance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Regenacy Pharmaceuticals product offering

Product offering

Core offering

Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company developing ricolinostat, a selective HDAC6 inhibitor drug candidate, as a potential first-in-class treatment for painful diabetic peripheral neuropathy (DPN). The product targets the underlying pathology of peripheral neuropathies rather than just symptomatic relief, and is being advanced through Phase 2 clinical trials with plans for international expansion including China markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ricolinostat

Companies that use Regenacy Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Regenacy Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Regenacy Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators3 records

Regenacy Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Global biopharma with established neuropathic pain assets (e.g., pregabalin/Lyrica history) and broad diabetes pipeline; competes with Regenacy in the same neuropathy treatment space via both approved products and ongoing R&D.
  • Eli Lilly: Major biopharmaceutical company with a large diabetes franchise (dulaglutide/trulicity) and significant R&D presence in diabetic complications including DPN, making it both a potential competitor and a natural acquirer of neuropathy assets like ricolinostat.
  • Daiichi Sankyo: Japanese global biopharma with strong Asia-Pacific commercial infrastructure and a neuropathy/pain franchise; comparable both as a potential competitor and as a natural strategic partner for a US-Japan cross-border clinical asset.
  • Astellas Pharma: Japanese global biopharma with active programs in diabetic complications and neurology; operates in the same therapeutic space and provides a natural regional commercialization partner for a US-developed neuropathy asset.

Direct peers

  • Applied Therapeutics: Clinical-stage biopharma developing mechanism-driven therapies for diabetic complications and rare diseases; similar in size, stage, and focus on high-unmet-need diabetic indications, making it a directly comparable small-cap peer.
  • Novaremed: Clinical-stage company developing a non-opioid therapy (NRD.E1) for painful diabetic peripheral neuropathy; a directly comparable small-cap peer targeting the same indication with a novel mechanism and similar development stage.
  • Lexicon Pharmaceuticals: Clinical-stage biopharma developing mechanism-driven therapies, with a history of programs in diabetic complications and neuropathic pain; a directly comparable small-cap peer with overlapping therapeutic area focus.

Emerging players

  • Viva Biotech: Asia-based discovery and development services/investor with biopharma incubation; comparable as both an investor in the same asset class and as an emerging player in the regional biopharma ecosystem in which Regenacy's syndicate operates.
  • Chromocell: Clinical-stage biotech developing novel therapeutics for pain and sensory disorders, including neuropathic pain; comparable in stage, scale, and therapeutic focus to Regenacy's single-asset DPN program.
  • Clexio Biosciences: Clinical-stage company developing therapies for neuropathic pain and other neurological conditions; similar in size and stage, and competing for the same patient population and payer attention as Regenacy.

Market position

Customer concentration

Regenacy Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regenacy Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Regenacy Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regenacy Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenacy Pharmaceuticals

What does Regenacy Pharmaceuticals do?

Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company developing ricolinostat, a selective HDAC6 inhibitor drug candidate, as a potential first-in-class treatment for painful diabetic peripheral neuropathy (DPN). The product targets the underlying pathology of peripheral neuropathies rather than just symptomatic relief, and is being advanced through Phase 2 clinical trials with plans for international expansion including China markets.

Is Regenacy Pharmaceuticals a public or private company?

Regenacy Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Regenacy Pharmaceuticals founded?

Regenacy Pharmaceuticals was founded in 2016. It employs 1 to 10 people.

Where is Regenacy Pharmaceuticals based?

Regenacy Pharmaceuticals is headquartered in Waltham, United States, in the North America region.

How does Regenacy Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Regenacy Pharmaceuticals's main competitors?

Broad incumbents on record are Pfizer, Eli Lilly, Daiichi Sankyo and Astellas Pharma. Direct peers are Applied Therapeutics, Novaremed and Lexicon Pharmaceuticals. Emerging players are Viva Biotech, Chromocell and Clexio Biosciences.

Does Regenacy Pharmaceuticals have an API?

No public API is recorded for Regenacy Pharmaceuticals.

What industry is Regenacy Pharmaceuticals in?

Regenacy Pharmaceuticals's product category is Peripheral Neuropathy Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineRegenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 Million Series B FinancingRegenacy Pharmaceuticals announced the completion of enrollment for its Phase 2 study of ricolinostat in treating painful diabetic peripheral neuropathy and closed a $9.3 million Series B financing round led by Cobro Ventures. The company intends to use the proceeds to continue advancing the clinical development program for ricolinostat, with initial results expected later in the year.Business Wire BlogRegenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 Million Series B FinancingRegenacy Pharmaceuticals announced the completion of enrollment for its Phase 2 study of ricolinostat in treating painful diabetic peripheral neuropathy and closed a $9.3 million Series B financing led by Cobro Ventures. The company intends to use the new funds to continue advancing the clinical development program for ricolinostat, with initial results expected later this year.SecSEC FORM DRegenacy Pharmaceuticals, Inc. filed a Form D with the SEC for an exempt offering of securities under Rule 506(b). The company reported total offering proceeds of $9,999,999 USD, with $7,808,997 sold to nine investors as of January 27, 2022. This filing serves as a regulatory notice for the equity offering.MedCity NewsThese health startups raised $124M in venture capital funding this weekFour healthcare startups raised $124M in venture capital this week: Aktiia, Bright.md, ReCode Therapeutics, and Regenacy Pharmaceuticals. The funds will support FDA clearance, AI-based virtual care expansion, preclinical development, and a Phase II trial for a drug.FinSMEsRegenacy Pharmaceuticals Secures $30M in Series A FinancingRegenacy Pharmaceuticals closed a $30M Series A financing co-led by Cobro Ventures and Taiwania Capital Management. The company will use the funds to initiate a Phase 2 proof-of-concept trial for ricolinostat in diabetic peripheral neuropathy, with prior studies showing a good safety profile. The drug may also be evaluated for chemotherapy-induced neuropathy and Charcot-Marie-Tooth disease.VC News DailyRegenacy Pharmaceuticals Inks $30M in Series ARegenacy Pharmaceuticals announced the closing of a $30 million Series A financing co-led by Cobro Ventures and Taiwania Capital Management, with participation from 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, and TA YA VENTURE HOLDINGS LIMITED. The clinical-stage biopharmaceutical company developing treatments for diabetic and other peripheral neuropathies plans to use the proceeds to advance its lead program ricolinostat into Phase 2 proof-of-concept trials for diabetic peripheral neuropathy. Ricolinostat is an oral, selective HDAC6 inhibitor that has demonstrated an excellent safety and tolerability profile in prior Phase 1 and 2 clinical studies and is also being evaluated for chemotherapy-induced peripheral neuropathy and Charcot-Marie-Tooth disease Type 2.